Results 51 to 60 of about 70,330 (230)
Advanced Science, EarlyView.Lysosome‐targeting chimeras (LYTACs) enable degradation of extracellular and membrane proteins via lysosomal trafficking. We report a novel IGF‐II mutant (Del1–7, Y27L) that selectively engages IGF‐IIR while avoiding IGF‐IR and IR‐A. mutIGF‐II–based LYTACs enhance target internalization and degradation and support a genetically encodable, all‐protein ...
Yuan Zhao +16 more
wiley +1 more source
Cancer Medicine, 2019 Purpose Combination of biological therapy and chemotherapy improves the survival of patients with metastatic colorectal cancer (mCRC). However, the optimal biological therapy sequence remains unclear.
Hung‐Chih Hsu +7 more
doaj +1 more source
Scientific Reports, 2021 Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is an efficient anti-tumor therapeutic agent that inhibits the activation of EGFR; however, data related to the cellular effects of prolonged cetuximab treatment are limited.
Kohei Okuyama +8 more
doaj +1 more source
NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer
Advanced Science, EarlyView.Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen +8 more
wiley +1 more source
Biomolecules, 2019 Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. Cetuximab, a human/mouse chimeric monoclonal antibody, is effective in a limited number of CRC patients because of cetuximab resistance.
Mee Hyun Jeoung +9 more
doaj +1 more source
Cancer Medicine, 2021 Background Cetuximab is used for colorectal cancer (CRC) treatment. However, the early biomarker of treatment efficacy of cetuximab has not been identified. Methods After 1 year of cetuximab treatment, patients were divided into an effective group and an
Xujun Zhang +10 more
doaj +1 more source
Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. [PDF]
, 2015 Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer.
Herman, June +3 more
core +3 more sources
Coacervate‐Mediated Lysosome‐Targeting Antibody Delivery for Protein Degradation
Advanced Science, EarlyView.Targeting coacervates to the lysosome in the cytoplasm is a challenge. Here, we convert a tetrapeptide into lysosome‐targeting, membrane‐translocating coacervates. The lysosome‐sorting peptide coacervates facilitate coacervate‐mediated delivery of antibody antigen complexes and a PROTAC compound to the lysosome for the targeted degradation of cancer ...
Dingdong Yuan +7 more
wiley +1 more source
Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells
Brazilian Journal of Medical and Biological Research, 2017 Cetuximab is widely used in patients with metastatic colon cancer expressing wildtype KRAS. However, acquired drug resistance limits its clinical efficacy. Exosomes are nanosized vesicles secreted by various cell types.
S. Zhang +12 more
doaj +1 more source
Adaptive immunity in cancer immunology and therapeutics. [PDF]
, 2014 Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core +2 more sources